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AfricaModern genomic approaches have made enormous contributions to improving our understanding of the func-
tion, development and evolution of the nervous system, and the diversity within and between species. However,
most of these research advances have been recorded in countries with advanced scientiﬁc resources and funding
support systems. On the contrary, little is known about, for example, the possible interplay between different
genes, non-coding elements and environmental factors in modulating neurological diseases among populations
in low-income countries, including many African countries. The unique ancestry of African populations suggests
that improved inclusion of these populations in neuroscience-related genomic studieswould signiﬁcantly help to
identify novel factors that might shape the future of neuroscience research and neurological healthcare. This
perspective is strongly supported by the recent identiﬁcation that diseased individuals and their kindred from
speciﬁc sub-Saharan African populations lack common neurological disease-associated genetic mutations. This
indicates that there may be population-speciﬁc causes of neurological diseases, necessitating further investiga-
tions into the contribution of additional, presently-unknown genomic factors. Here, we discuss how the develop-
ment of neurogenomics research in Africa would help to elucidate disease-related genomic variants, and also
provide a good basis to develop more effective therapies. Furthermore, neurogenomics would harness African
scientists' expertise in neuroscience, genomics and bioinformatics to extend our understanding of the neural
basis of behaviour, development and evolution.
© 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Human populations globally show genetic and genomic diversity.
Improved understanding of this diversity can provide information that
would shape the future of basic, applied and translational medicine
(Gurdasani et al., 2015). Until recently, not much was known about
genomic diversity among the different African populations. However,
recent developments in research funding, training and infrastructure
are making important contributions to building genomics research
capacity on this continent (H3Africa Consortium et al., 2014). This
means that major biomedical research questions relevant to the
African population can be addressed by research scientists working in
Africa. A signiﬁcant example is the recent sequencing and assembly
of the tsetse ﬂy genome which is aiding in-depth studies into Human
African trypanosomiasis disease biology (International Glossina
Genome Initiative, 2014). Additionally, whole genome sequencing
and bioinformatic analyses of patients' genomes during the recent
Ebola virus disease outbreak provided vital information on disease epi-
demiology and future directions (Gire et al., 2014). The African Genome
Variation Project also recently characterised genomic variations among
certain key African ethnic groups (Gurdasani et al., 2015). These devel-
opments are a few examples demonstrating that genomics hold a lot of
promise for biomedical research and medical care in Africa, particularly
in providing insights into individual and population variations in dis-
ease susceptibility and resistance, as well as differential drug responses.
The decreasing costs of high-throughput sequencing technologies also
offer an opportunity to African laboratories in acquiring such technolo-
gies to advance their research activities (Karikari, in press).
While genetics refers to the study of single genes and their associated
biological effects, genomics is usually concerned about studying the
totality of genes and non-coding elements in an individual's genome
(i.e., the complete collection of genes and genetic material in the organ-
ism), in order to identify how these components function individually
or collectively. Due to the wide coverage of sequencing technologies,
it has been possible to extensively characterise genetic variants in
populations studied to date, as well as gain in-depth insights into
disease mechanisms and the development of potential therapies.
Genomic diversity may lead to variations in the neural basis of develop-
ment (neurodevelopment), behaviour (neurobehaviour), evolution
(neuroevolution) and drug response (neuropharmacology); the study
of these areas is referred to as neurogenomics (Boguski and Jones,
2004; Chandrasekaran et al., 2011; Deriziotis and Fisher, 2013; Tsuji,
2013). While genomics research is developing in Africa, there is limited
application of these advances in neuroscience. Here, we discuss that the
further development of neurogenomics in Africa would help to obtain
further genomic-scale insights into neurological diseases, through the
combined efforts of expertise in neurobiology, genome science and
bioinformatics.2. Neuroscience research in Africa
Comprehensive acounts of the state of neuroscience in Africa have
been previously provided (Karikari et al., in press; Yusuf et al., 2014).
Regardless of the many challenges in research funding, expert training
and research infrastructure, signiﬁcant progress has been recorded in
developing neuroscience research capacity in Africa (Karikari et al., inpress). The area appears to be dominated by neuropharmacognosy
research; many studies investigate the disease-modifying beneﬁts
of administering herbal extracts and other natural products to experi-
mental organisms. African researchers are in a unique position of having
access to ecosystems of high biodiversity in combination with knowl-
edge of traditional medicine, the scientiﬁc testing of which may
lead to the discovery of new bioactive compounds. Complementing
neuropharmacognosywith neurogenomics can help to extend the ﬁnd-
ings of current research, by focusing on molecular disease mechanisms,
characterising in-depth the genomic effects of the compounds, and
usingbioinformaticsmethods to predict drug efﬁcacy, in order to poten-
tially match different compounds with diseases that they would work
on. These approaches could also be used to characterise the effects of
each drug in different genetic backgrounds, aiding research into preci-
sion medicine and improving patient treatment. If appropriately
employed, neurogenomics would help to strengthen molecular phar-
macognosy, drug development and the growing herbal medical indus-
try in Africa (Street and Prinsloo, 2012; van Andel et al., 2012).
Invertebrate model organisms such as Drosophila melanogaster have
been introduced to African neuroscientists as powerful-yet-low-cost al-
ternatives to themammalianmodels often used (Karikari et al., in press;
Muindi and Keller, 2015; Yusuf et al., 2014). The genomically simple
organismD.melanogaster has been used extensively in neuroscience re-
search worldwide, especially in investigating the neural basis of devel-
opment, behaviour, evolution, and disease (Allen et al., 1998; Carhan
et al., 2003; Eddison et al., 2011; Karikari et al., 2015a; Reeve et al.,
2007). Their simple genomes; short life spans and reproduction cycles;
and powerful genetic, biochemical and structural tools are some of the
advantages that make invertebrate systems useful for genetics-related
research (Moffat, 2008). The inexpensive maintenance of inverterbrate
organisms in experimental conditions also makes them particularly
beneﬁcial in areas of low research funding (Moffat, 2008).3. Clinical neuroscience in Africa
Expertise in clinical neuroscience disciplines (such as neurosur-
gery, neuropsychiatry and clinical neurology) is essential to collect
neurogenomics data from human subjects, analyse and make infer-
ences from these data and also to integrate genomic approaches
into clinical diagnosis and treatment processes in order to advance
the wellbeing of patients and improve efﬁciency in healthcare delivery.
To develop neurogenomics research and application in African health
facilities, interdisciplinary collaborations in this area need to be encour-
aged, for example through meetings and training courses. Further to
this, more clinicians in neuroscience-related specialties should be
trained in the clinical applications of genome science, to enable them in-
corporate the new knowledge into clinical procedures to improve the
timeliness and accuracy of disease diagnosis and treatment. In areas
where clinical neuroscientists are lacking, general practitioners with
the appropriate training can help to integrate neurogenomics in clinical
settings.
While neurology started in Africa (Egyptian physicianswere theﬁrst
to describe the brain, and also recognised major brain-related diseases
(Martín-Araguz et al., 2002)) and neurology practice can be traced to
native African physicians many millenia ago (for example, native
Yoruba physicians in Nigeria practised neurology in a traditional way
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human resources and facillities for neurology practice (Owolabi et al.,
2007). Generally, clinical neuroscientists are lacking across Africa, with
low neurologist-to-population ratios recorded in many countries.
While the best-ranked countries have one neurologist per 162,885 res-
idents, ranking close to the United States (US) and European countries
that have a neurologist for between every 40,000-125,000 residents,
in contrast, the least resourced countries have no resident neurologist
(Owolabi et al., 2007). Ghana, for instance, has only a couple of
neurologists serving a population of about 26 million (Drislane et al.,
2014a). Compared with leading countries such as the US where the
neurologist:population ratio is about 1:29,200, a neurologist in the
African country with the highest neurology workforce serves about six
times more people (Owolabi et al., 2007). The neurologist-to-population
ratios all over Africa fall behind the one neurologist to 100,000 persons
ratio recommended by the World Health Organization (Bower and
Zenebe, 2005). The dearth of neurologists in Africa has negative impli-
cations for clinical neuroscience practice, teaching and research. Neu-
rology research is poor on the continent; a survey identiﬁed that the
number of articles with authors/co-authors afﬁliated to African institu-
tions and published in leading neurology journals were very low com-
pared to the total number of articles (for example, only seven out of
over 1500 articles published in four leading neurology journals in
2005 had authors afﬁliated to African institutions) (Owolabi et al.,
2007). Since most neurologists do practise in cities, the majority of
Africans who reside in rural areas have difﬁculty accessing neurological
care (Bower and Zenebe, 2005). Additionally, not much information is
documented about neurology training programmes in Africa, although
there is a general lack of residency programmes (Bergen and Good,
2006). Nonetheless, the situation seems to be improvingwith the estab-
lishment of pro-rural medical residency programmes (Drislane et al.,
2014b). Also, the International Parkinson andMovement Disorder Soci-
ety and theWorld Federation of Neurology have been organising train-
ing courses for non-neurology specialist clinicians inWest Africa, aimed
at improving their knowledge in neurology to aid clinical practice (Cilia,
2013). More programmes of this nature would be essential to improve
the capacity of clinicians for neurogenomics use in Africa.
4. Neurogenomics: an opportunity to develop and apply genomic
tools to advance neuroscience in Africa
The genome sequence differences recorded among African popula-
tions and also between Africans and other populations suggest a need
for additional research aimed at identifying how these variations
might lead to neurogenomic differences. In this section, we discuss
how neurogenomics would support biomedical research and medical
care in neurology, neurobehaviour and neurodevelopment, and pro-
mote pan-African collaborative research in neuroscience, genomics,
and bioinformatics.
4.1. Studying genomic basis of neurological diseases
Most of the studies on neurological diseases in Africa have been fo-
cused on disease epidemiology, conducted among limited populations
in a fewcountries (Lekoubou et al., 2014). Only a fewstudies investigating
the molecular and genetic aspects of these diseases among Africans exist
(Blanckenberg et al., 2013). Signiﬁcantly, most studies conducted among
sub-Saharan Africans found that common disease-associated geneticmu-
tationsweremissing inpatients' genomes (Blanckenberg et al., 2013; Cilia
et al., 2012; Logue et al., 2011; Quansah and Karikari, in press;
Yonova-Doing et al., 2012). On the contrary, some of these mutations
have been identiﬁed in diseased individuals in North Africa (Lesage
et al., 2009), suggesting that the genetic causes of these diseases may be
population-speciﬁc. Notably, the LRRK2 G2019S mutation in Parkinson's
disease is believed to have originated from common founder mutations
from Middle East and North Africa (Zabetian et al., 2006). The absenceof this and other disease-associated mutations among sub-Saharan
African study subjects suggests that common disease mutations are un-
likely to be the causes of some neurological diseases within this popula-
tion; this may have serious implications for disease treatment. For
example, drugs that work for diseased individuals within one population
may not work for the other. This necessitates further investigation to
identify the role of additional, presently-unknown genetic factors respon-
sible for neurological diseases in Africa (Quansah and Karikari, in press;
Yonova-Doing et al., 2012). Better understanding of the genetic causes
of these diseases among and between African populations would be a
key step in advancing molecular mechanisms that regulate the diseases,
which would also lead to the development of better-targeted therapies.
Furthermore, the above ﬁndings support the idea that there is an urgent
need for long-term planning and support to prepare the continent for
the estimated future increases in the burden of neurological diseases, as
well as the economic, health and social burdens usually associated with
these diseases (Dua et al., 2006; Lekoubou et al., 2014).
4.2. Genome-level studies into neurobehaviour
Within the animal kingdom, incredible diversity in behaviour exists.
The decisions of many animals, including humans, who live in complex
social environments are often dependent on their interactions with
other individuals (Harris and Hofmann, 2014). Social and reproductive
behaviours vary among animal species; interestingly, genomic variants
have been found to inﬂuence these behavioural differences (Harris and
Hofmann, 2014). The application of genomic techniques has enabled
scientists to obtain insights into the molecular and neural basis of or-
ganismal behaviour and decision-making, as well as how these features
have evolved over time (Harris and Hofmann, 2014; O'Connell and
Hofmann, 2011). It is believed that speciﬁc genes or gene products con-
comitantly regulate these behaviours, although the evidence base is
weak as to whether these behaviours are evolutionarily conserved or
are affected by environmental factors, and why it would be so (Harris
and Hofmann, 2014; Oers and Mueller, 2010). Further studies may
lead to the identiﬁcation of novel genes or other genome regions mod-
ulating behavioural traits in different social contexts, and how gene ex-
pression levels, gene networks, gene–environment interactions, gene
products or pleiotropic elements may affect personality phenotypes in
different ecological settings (Oers and Mueller, 2010). The African con-
tinent is a promising area for this type of research, due to its very high
biodiversity, as well as very high social diversity and range of sub-
populations. Different high throughput techniques can be used here, in-
cluding genome sequencing to characterise population-based genetic
variants, possibly followed by RNA sequencing and epigenetic studies.
Already, various genomic factors have been shown to be playing roles
in behavioural conditions such as alcoholism, and nicotine and cocaine
addiction (Caron et al., 2005; Heberlein et al., 2009; Mulligan et al.,
2011). Since various model organisms are used in this area of research,
platforms such as ENCODE, modENCODE and InterMOD that allow the
integration of genomic data and tools to support cross-species research
may be useful here, and provide publicly-available data to use as a
starting point for research (Gerstein et al., 2010; Roy et al., 2010;
Sullivan et al., 2013; The ENCODE Project Consortium, 2004).
4.3. Genomic studies into neurodevelopment
During organismal development, speciﬁc changes in gene expres-
sion are required for differentiation and body plan development
(Aleksic et al., 2013; Allen et al., 1998; Easter et al., 1996; Kimmel
et al., 1995; Reeve et al., 2007; Shen et al., 2013; Singh et al., 2014).
Tissue-speciﬁc gene expression is usually conserved across species;
disruption to the amount or timing of expression could affect multi-
ple molecular pathways leading to neurodevelopmental impair-
ments (Nüsslein-Volhard and Wieschaus, 1980; Zhu et al., 2014).
Neurodevelopmental disorders can include developmental brain
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language, speech, motor, and non-verbal communication functions
(Zhu et al., 2014). Although genomic factors have been shown to be in-
volved in the biology of neurodevelopmental disorders (Deriziotis and
Fisher, 2013; Tsuji, 2013), the evidence from African populations is
scanty. Given that African populations have a unique lineage, and are
often distinct from the non-African populations on whom most avail-
able research has been conducted, it might be interesting to ascertain
whether future research focused on or involving Africans would pro-
vide novel ﬁndings. This would improve future genetic diagnosis in
the area of neurodevelopmental diseases for the African population.
This is also relevant for drug development, the testing of drug safety,
and for the emerging ﬁeld of precision medicine, which requires
the right background populations to be studied in detail. While
neurodevelopmental disorders are beginning to attract research at-
tention in Africa, culture still has a huge effect on the perceptions
and care for people suffering from such disorders (Bakare and Munir,
2011;Ndung'u andKinyua, 2009). Aside from increasing research efforts,
public-focused outreach initiatives discussing neurodevelopmental
disorders and neuroscience advances will be needed (Karikari et al.,
2015b).
4.4. Development and application of neurogenomic tools in clinical
diagnosis and treatment
Relying on disease symptoms, instead of molecular markers, for
diagnosing and treating neurological and neuropsychiatric disorders
poses a challenge to clinicians, including the risk of false positives,
due to overlapping clinical symptoms often presented by patients
(Rickards, 2005). This challenge is much more acute in Africa where
many healthcare institutions and professionals are unequipped with
molecular and genetic diagnostic platforms. Importantly, the discovery
that some biomarkers (such as disease-causing genetic mutations) are
absent from speciﬁc African populations also indicates that common
diagnostic and treatment options may not necessarily work for them.
It is therefore essential that further research is conducted to identify
novel, clinically-relevant disease biomarkers that will improve the
development and application of genomic tools in the neurology clinic
in Africa. Altogether, increasing neurogenomics research and use in
Africa would help to improve speciﬁcity and timeliness of clinical
diagnosis and treatment of neurological diseases.
4.5. Pan-African collaborative research and training in neuroscience,
genomics and bioinformatics
Neurogenomics requires the involvement of a broad scientiﬁc com-
munity (Insel et al., 2004). It provides collaborative opportunities for
scientists with expertise in areas such as neuroscience, genomics and
bioinformatics. While neuroscientists would bring their skills and
knowledge in experimental neurobiology, genomics researchers
would complement thesewith expertise in the design and implementa-
tion of high-throughput sequencing technology-based experiments.
Also, since modern sequencing approaches require familiarisation
with informatics tools and techniques needed to accession samples, an-
alyse data and report ﬁndings (Sharma et al., 2013), bioinformaticians
would also be needed in neurogenomics research projects. These ﬁelds
are either established or developing areas in Africa, with considerable
scientiﬁc capacity available (Bishop et al., 2015; H3Africa Consortium
et al., 2014; Karikari, in press; Yusuf et al., 2014). The increasing infra-
structural and funding investments in genomics-related research in
Africa provides opportunities to identify scientists with interests in
these areas, and collaborate to answer questions of relevance to
neurogenomics. The establishment of genomic sample repositories in
key African institutions, such as those established by the H3Africa Con-
sortium, will also provide great beneﬁt in this area (Adoga et al., 2014;
H3Africa Consortium et al., 2014). Signiﬁcant examples of these beneﬁtswill include improved cost- and time-effectiveness in accessing ar-
chived samples for neurogenomics experiments (H3Africa Consortium
et al., 2014). Importantly, the established guidelines on genomic sample
collection, data sharing and research collaboration in Africa will also be
useful in this regard, ensuring fairness and transparency, as well as sci-
entiﬁc replicability (de Vries et al., 2015). Collaborative research efforts
in neurogenomics (whether between scientists in the same institution,
country or even inmultiple countries) would also present many oppor-
tunities to scientiﬁc knowledge advancement in Africa, such as student
training and clinical care. For example, improved understanding of the
genomic and molecular underpinnings of memory, attention and stress
can contribute to improving learning and education (Edelenbosch et al.,
2013).
Additionally, improved neurogenomics research in Africa would
help to develop student training in this area. This is because developing
research facilities often leads to increased student access to equipment
and expert training. Teaching neuroscience, like many other scientiﬁc
disciplines, is a challenging endeavour in Africa due to the lack of exper-
imental resources (Karikari, 2015a; Karikari et al., 2015b). To overcome
this challenge, scientists in bench research-intensive disciplines have
been encouraged to partner with their colleagues in the computational
sciences, to jointly develop alternative teaching approaches (Karikari,
2015b). Neurogenomics would support student training through, for
example, the involvement of students in the application of web-based
bioinformatics tools for predicting and analysing speciﬁc conditions.
The low-cost nature of bioinformatics combined with the availability
of large quantities of free, publicly-available genomics data, presents
many opportunities in this area (Karikari, in press).
5. Advantages and challenges of neurogenomics research and use
in Africa
While Africa has some unique features that would enable
neurogenomics research and application, speciﬁc challenges need
to be addresed to enable this transformation. In this section, we
highlight these enabling factors as well as the weaknesses that
should be tackled. A summary of this discussion is provided in
Table 1.
5.1. Advantages
The relatively less-studied genetic diversity, unique gene-
environment interactions and local traditional medicine practice
are some of the potential advantages of neurogenomics in Africa. More-
over, the growing research interest in genomics aswell as the establish-
ment of research funding, data and sample repository systems provide
essential platforms and foundations for this area of research.
5.1.1. High genetic diversity
African populations have higher levels of genetic and phenotypic di-
versity and extensive population substructure compared to non-African
populations (Campbell and Tishkoff, 2008; Gomez et al., 2014). It is be-
lieved that modern humans originated in Africa many years ago and
some subsequentlymigrated to other parts of theworld; this is often re-
ferred to as the out of Africa migration (Ashraf and Galor, 2011; Gomez
et al., 2014). This makes the genetic study of African populations inter-
esting, since it might provide further clues into the genetic basis of evo-
lution and adaptation. Furthermore, the genetic diversity and
adaptation among Africans have evolved over time in response to di-
verse conditions such as diseases, climates and diets (Campbell and
Tishkoff, 2008). Notable examples of genetic-dependent disease suscep-
tibility and resistance among Africans have been previously shown in
tuberculosis and malaria, respectively (Thye et al., 2012; Timmann
et al., 2012). As indicated above, this population-based genetic differ-
ence also appears to regulate predisposition to some neurological dis-
eases. The rich genetic diversity among and between African
Table 1
Summary of advantages and challenges of neurogenomics in Africa.
Advantages Challenges
High genetic diversity and varying
gene-environment interactions
among and between African popula-
tions serve as valuable resources for
studying genomic regulation of
exposure to, and protection from,
speciﬁc diseases.
Lack of a high number of
appropriately-trained scientists and
clinicians to lead neurogenomic
activities is challenging to the
development of the ﬁeld.
The practice and knowledge of
traditional medicine provides an
opportunity to open up new research
areas in order to search for bioactive
compounds.
The low availability of research and
clinical resources for genomics use is a
limiting factor for research.
Potential contribution of traditional
medicine to drug discovery and
development as well as drug safety
and efﬁcacy evaluation.
Potential problems in the ethical, legal
and social implications of genomic data
collection and use might affect
participant vulnerability and the
willingness of populations to enrol in
studies.
Neurogenomics would help to extend
existing neuropharmacognosy
research in Africa, by helping to pro-
vide further insights into the molecu-
lar mechanisms of disease and
disease-modifying beneﬁts of bioac-
tive compounds.
Inadequate funding of genomics
research by African governments leaves
the sustainable development of the ﬁeld
in a questionable state.
Established genomic data sharing
frameworks would ensure fairness in
data collection, sharing and use.
Neurological problems associated with
non-neurological diseases might be
challenging to study, especially among
laboratories with limited resources.
Recent genomic research funding and
capacity-building programmes by
speciﬁc international agencies are
helping to establish good foundations
and platforms for this area of research
in Africa.
Interest in genomic research is growing
among African scientists; this is
helping to build a large number of
scientists with expertise in genomic
technologies as well as institutions
with the required facilities.
Decreasing costs of sequencing
technologies also provide an
advantage to laboratories with limited
funding to be able to afford such
resources.
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disease susceptibility, resistance and propagation, as well as the evolu-
tionary history behind these characteristics. The long histories shared
by African populations provide prospects for improving the accuracy
of ancestral haplotype construction (Peprah et al., 2015). Broadening
genomic studies to include Africa's diverse ethnic groups would en-
hance understanding into differential neurological disease risks, and
the application of this knowledge to enhance drug development and
disease treatment.
5.1.2. Traditional medicine
Traditional medicine used to be the most dominant healthcare
delivery system in the pre-colonial era in Africa (Abdullahi, 2011).
This means that traditional treatment of disease, including neurological
conditions, has been around for several centuries (Osuntokun, 1975).
Currently, traditional medicine remains as a frequently-used and
trusted source of care for a good proportion of the African population,
especially in rural areas where conventional medical facilities are
lacking (Abdullahi, 2011). While the lack of standard procedures and
regulatory frameworks sometimes make the reliability of traditional
medicine questionable, efforts have been made recently to streamline
and regulate this system in several African countries, aswell as integrate
it into the orthodox healthcare delivery system. These efforts includethe establishment of degree programmes in herbalmedicine and the in-
tegration of graduates from these programmes into national health de-
livery systems to partner with orthodox physicians (Adusi-Poku et al.,
2009; Ministry of Health, Republic of Ghana, 2007). African traditional
healers usually classify various natural products according to product
potency and diseases on which they act (Mahomoodally, 2013). How-
ever, most of this knowledge remains as undocumented indigenous
knowledge. While reports on the effectivenesss of such products are
available, the fact that they have not been studied in detail, especially
in terms of their modes of action necessitates further studies
(Mahomoodally, 2013). For instance, the application of genomic tech-
niques would support bioactive compound discovery from plant prod-
ucts, as well as drug safety and effectiveness evaluation. This approach
might lead to the identiﬁcation and development of new and more ef-
fective natural product-based therapeutic agents. Moreover, the in-
creasing drug resistance problem and the shortage of drug candidates
in the discovery pipeline suggest that partnering with traditional med-
ical practitioners whomight be aware of potential drug candidates over
the years may prove to be a useful venture.
5.1.3. Growing research interest in genomics
African researchers have joined genomics research activities with
considerable interest and effort. Thanks to funding, infrastructure and
training support from organisations such as the National Institute of
Health and the Wellcome Trust, more African scientists are gearing up
for genomics applications in biomedical research and clinical care
(Adoga et al., 2014; H3Africa Consortium et al., 2014; Karikari, in
press). Important examples here include the establishment of the
Human Health and Heredity in Africa (H3Africa) programme which is
aimed at supporting health-related genomics research in Africa, and
the H3ABioNet which is helping to build expertise and collaboration in
bioinformatics and genomics-related research in the continent. Further
details about these programmes have been given elsewhere (Adoga
et al., 2014; Bishop et al., 2015; H3Africa Consortium et al., 2014;
Karikari, in press). Such capacity-building initiatives provide good
platforms for scientists to collaborate and share resources to advance
genomics research in Africa.
5.2. Challenges
Potential impediments include the low availability of expertise and
resources in some countries for both experimental and clinical use of
neurogenomics, as well as challenges in data sharing, pan-African col-
laborative research and the burden of diseases with neurological
complications.
5.2.1. Lack of experimental and clinical resources and expertise
Genomics research is relatively new tomost research and clinical in-
stitutions in Africa. For this reason, many of such institutions lack
appropriately-trained scientists and the needed experimental resources
(Karikari, in press; Mohamed, 2015). Currently, only a few leading
institutions in Africa can be considered adequately-resourced for geno-
mics applications (Bishop et al., 2015; Fatumo et al., 2014; H3Africa
Consortium et al., 2014; Karikari, in press). This has negative
consequences on student training, research capacity building, as well
as research and healthcare delivery outcomes (H3Africa Consortium
et al., 2014; Karikari, in press; Mohamed, 2015).
5.2.2. Ethical collection, sharing and re-use of neurogenomic data
As a new ﬁeld to Africa, the ethical, legal and social implications of
neurogenomics data collection and use have not been well-studied
and documented, and might therefore pose a challenge to the advance-
ment of the ﬁeld. While African genomic data policy frameworks have
been established, ethical considerations in the collection, sharing and
re-use of genomic data remains a challenge (de Vries et al., 2015). Of
particular concern is the use of samples and data that can identify
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(de Vries et al., 2014). Another issue is the ethical approval for genomic
data usage (both primary and secondary use), especially among people
of low educational levels and limited access to healthcare who might
not adequately appreciate the need for their consent before being
enrolled in genomic studies and might also interpret their inclusion in
such studies as a favour (Wright et al., 2014). The under-resourced
nature of many ethical review committees also often makes it difﬁcult
for them to appropriately regulate genomics research on the continent
(Wright et al., 2014). Efforts should therefore bemade to address partic-
ipant vulnerability and other ethical issues in genomics research in
Africa.
5.2.3. Lack of intra-continental collaborative research and research funding
Another potential challenge is the current lack of intra-continental
collaborative research efforts in genomics, particularly in studying the
genomic aspects of neuroscience (Karikari, in press; Karikari et al., in
press). African scientists collaborate more often with their colleagues
working out of Africa, compared to scientists afﬁliated to African institu-
tions (Karikari, in press; The World Bank, 2014). This might be due to
the often better-resourced nature of research groups in the developed
world (both in terms of funding and laboratory resources), which
possibly serve as natural attractants to their colleagues in developing
countries. However, to be able to jointly identify and conduct research
into Africa-focused challenges, more scientists working on the conti-
nent will need to combine their efforts and expertise (Karikari, in
press; Karikari et al., in press). Furthermore, to promote intra-
continental research and ensure that research directions are better
aligned with the continent's developmental priorities, improved re-
search funding especially from African governments and other local
agencies will be required (Karikari, in press; Karikari et al., in press).
5.2.4. Heavy burden of diseases with associated neurological problems
Diseases such as malaria, Human Immunodeﬁciency Virus/Acquired
Immune Deﬁciency Syndrome (HIV/AIDS), tuberculosis, and the
neglected tropical diseases account for a high percentage of the disease
and healthcare burden in Africa (Human Development Network — The
World Bank and Institute for Health Metrics and Evaluation —
University ofWashington, 2013). Neurological problems are often asso-
ciated with these diseases (Bangirana et al., 2011; Cherian and Thomas,
2011;Mireku et al., 2015; Robertson et al., 2010). This situation presents
both a challenge and an opportunity to extend neurogenomics applica-
tions in Africa. While the complicated nature of investigating multiple
diseases (for example, infectious diseases and their associated neuro-
logical problems) might prove challenging to scientists with
inadequately-resourced laboratories, it would also provide an opportu-
nity to explore how speciﬁc diseases (especially those prevalent in
Africa) can affect neurological functions.
6. Introducing neurogenomics training in Africa
To help build capacity for neurogenomics in Africa, a few organi-
sations have taken leading roles in offering training programmes for
resident scientists. The H3ABioNet nodes (centres of excellence)
across the continent regularly organise training programmes in geno-
mics techniques and data analysis to interested scientists (Karikari, in
press). Scientiﬁc societies such as the African Society for Bioinformatics
and Computational Biology and the African Society for Human Genetics
also provide capacity-development support in this area. To further ex-
tend this support system, non-proﬁt organisations such as Teaching
and Research in Natural Sciences for Development in Africa (TReND in
Africa; http://trendinafrica.org) also organise training programmes in
neuroscience and genomics data analysis for African scientists. These
include annual neuroscience summer courses during which partici-
pants selected from across Africa are trained in how to use poweful-
yet-cost-effective model organisms, tools and techniques for geneticand genomic studies (Baden et al., 2015; Karikari et al., in press; Yusuf
et al., 2014). Additionally, TReND in Africa organises courses in next
generation sequencing data analysis, to train African scientists in how
to analyse and interpret genomic data. This course, which has been
held at the International Centre of Insect Physiology and Ecology
(ICIPE) in Kenya, is to expand to other countries including Nigeria and
Ghana in the near future. To help overcome the lack of experimental fa-
cilities and the high-cost involved in purchasing new ones, TReND in
Africa also trains African scientists in how to build their own laboratory
equipment through the use of open source resources (Baden et al.,
2015; Karikari et al., in press).
7. Conclusion
Neurogenomics is an emerging ﬁeld with enormous potential to
advance neuroscience-related biomedical research and healthcare in
Africa. However, studies exploring neurogenomic aspects of disease in-
cidences, risk and propagation among Africans are lacking. The discov-
ery that some African populations lack common disease-associated
genetic mutations highlights the need and urgency for further studies.
Gaining insight into the genomic causes of neuronal diseases in Africa
would help to improve the timeliness and accuracy of clinical diagnosis
and treatment. The use of existing genomics research facilities, as well
as the establishment of new facilities dedicated to neurogenomics
research would signiﬁcantly beneﬁt the continent. Importantly, sub-
stantial and sustainable ﬁnancial investments towards training scien-
tists and clinicians will be needed for Africa to fully beneﬁt from this
important research area.
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